Levodopa test

PreclinicalSmall molecule

UUniversity Hospital, Toulouse

Levodopa test is one of 29 small molecule programs targeting Multiple System Atrophy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple System AtrophyActive, not recruiting

Multiple System AtrophyPreclinical

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Multiple System Atrophy

#DrugCompanyPhaseTrials

Northera

Rifadin

Sudafed

Rilutek

AAzurity Pharmaceuticals

Rifampicin

1 6

Byetta

AstraZeneca

Phase 2

—7

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 2

1 8

Rapamune

PPrism Pharmaceuticals

Phase 2

1 9

Lithobid

SSolvay Pharmaceuticals

Phase 2

1 10

Immunoglobulin

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Multiple System Atrophy1 trial

Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Multiple System Atrophy

Completed·UUniversity Hospital, Toulouse·N/A·NCT01577992·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Levodopa test. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Levodopa test compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Levodopa test. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Toulouse company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Toulouse

Levodopa test

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Multiple System Atrophy1 trial

References

Drug Info

Quick Facts

Related News